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Background:  Monocyte chemotactic proteins (MCP) play important role generating intimal hyperplasia in stents. Bindarit (BND), a selective 
inhibitor of MCP synthesis, reduces intimal hyperplasia in animal models. In this first-in-man trial, we tested the efficacy and safety of BND to inhibit 
intimal hyperplasia following coronary stenting.
Methods: A phase II, double-blind, multi-centre randomized trial, included 108 patients with 128 lesions in 23 centres (3 countries). Patients were 
randomized into 3-arms (BND 600 mg, n=35; BND 1200 mg, n=34; placebo, n=39). Treatment started the day of the procedure and continued for 
180-days following PCI with bare metal stents (Multi-Link Vision). Monthly clinical follow-up and 6-month coronary angiography were conducted. 
In-segment late loss and in-stent loss were primary and secondary end-points.
Results: The 3 groups had no significant differences in the demographics. Treatment compliance was > 90%. Figure 1 shows Results: There were 
no significant side effects.
Conclusions: The significant reduction of in-stent late loss suggests a possible role of BND to decrease in-stent proliferation. Dosages higher than 
600 mg did not show additional advantage. A larger study utilizing a pre-treatment or a loading dose may be warranted.
